Medtronic, Inc. wasn’t the only company making China news this past month.
TranS1 Inc. Enters Middle Kingdom
1 min read Premium comments
Secondary
On October 10, Wilmington, North Carolina-based TranS1 Inc. announced the signing of a distribution agreement with Beijing Jiade Sunshine.
The distribution agreement covers the sale of AxiaLIF products in China with the exception of Hong Kong, Macau and Taiwan. The company’s AxiaLIF implants were granted a registration certificate by the State Food and Drug Administration (SFDA) and the remaining instrumentation is expected to receive its respective registration in the fourth quarter of 2012.
“The knowledge gained in the 13, 000 AxiaLIF cases completed in the U.S. and Europe combined with our strong focus on surgeon training will help to drive success in China, ” said Ken Reali, president and CEO of TranS1. “The Chinese spinal fusion market is large and growing and we believe the minimally invasive AxiaLIF lower lumbar fusion system will represent an attractive option for surgeons and their patients.”
“We are delighted to enter a long term partnership with TranS1 to offer such an innovative technology as AxiaLIF to spine surgeons and patients throughout China, ” said Ming Ming Tian, president of Jiade. “Minimally Invasive Spine Surgery (MISS) is rapidly expanding in China, and our vast, spine experienced, national distribution network is well positioned to advance adoption of this unique, but tested, MISS technology to present to their surgeons.”
Beijing Jiade Sunshine, a joint-stock enterprise, is a national distribution company in The People’s Republic of China. Jiade currently markets implants and other operating room products to spine and orthopedic surgeons. Jiade has made investments in developing experienced surgical marketing, professional sales and academic training teams throughout the Chinese market. Jiade was founded in March 2007.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.